156 related articles for article (PubMed ID: 22357252)
1. A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study.
Sehouli J; Runnebaum IB; Fotopoulou C; Blohmer U; Belau A; Leber H; Hanker LC; Hartmann W; Richter R; Keyver-Paik MD; Oberhoff C; Heinrich G; du Bois A; Olbrich C; Simon E; Friese K; Kimmig R; Boehmer D; Lichtenegger W; Kuemmel S
Ann Oncol; 2012 Sep; 23(9):2259-2264. PubMed ID: 22357252
[TBL] [Abstract][Full Text] [Related]
2. Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy.
Braicu EI; Fotopoulou C; Chekerov R; Richter R; Blohmer J; Kümmel S; Stamatian F; Yalcinkaya I; Mentze M; Lichtenegger W; Sehouli J
Cytokine; 2013 Mar; 61(3):755-8. PubMed ID: 23415672
[TBL] [Abstract][Full Text] [Related]
3. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group.
Marnitz S; Martus P; Köhler C; Stromberger C; Asse E; Mallmann P; Schmidberger H; Affonso Júnior RJ; Nunes JS; Sehouli J; Budach V
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):243-53. PubMed ID: 26853333
[TBL] [Abstract][Full Text] [Related]
4. Neo-adjuvant platinum-based chemotherapy followed by chemoradiation and radical surgery in locally advanced cervical cancer (Lacc) patients: A phase II study.
Ferrandina G; Palluzzi E; Gallotta V; Gambacorta MA; Autorino R; Turco LC; Macchia G; Cosentino F; Gui B; Mattoli MV; Ronzino G; Valentini V; Scambia G
Eur J Surg Oncol; 2018 Jul; 44(7):1062-1068. PubMed ID: 29753611
[TBL] [Abstract][Full Text] [Related]
5. Weekly cisplatin therapy compared with triweekly combination chemotherapy as concurrent adjuvant chemoradiation therapy after radical hysterectomy for cervical cancer.
Lee HN; Lee KH; Lee DW; Lee YS; Park EK; Park JS
Int J Gynecol Cancer; 2011 Jan; 21(1):128-36. PubMed ID: 21330837
[TBL] [Abstract][Full Text] [Related]
6. Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study.
DiSilvestro PA; Ali S; Craighead PS; Lucci JA; Lee YC; Cohn DE; Spirtos NM; Tewari KS; Muller C; Gajewski WH; Steinhoff MM; Monk BJ
J Clin Oncol; 2014 Feb; 32(5):458-64. PubMed ID: 24395863
[TBL] [Abstract][Full Text] [Related]
7. Chemoradiation with paclitaxel and carboplatin in high-risk cervical cancer patients after radical hysterectomy: a Korean Gynecologic Oncology Group study.
Lee TS; Kang SB; Kim YT; Park BJ; Kim YM; Lee JM; Kim SM; Kim YT; Kim JH; Kim KT
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):304-10. PubMed ID: 23642625
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial comparing concurrent chemoradiation versus concurrent chemoradiation followed by adjuvant chemotherapy in locally advanced cervical cancer patients: ACTLACC trial.
Tangjitgamol S; Tharavichitkul E; Tovanabutra C; Rongsriyam K; Asakij T; Paengchit K; Sukhaboon J; Penpattanagul S; Kridakara A; Hanprasertpong J; Chomprasert K; Wanglikitkoon S; Atjimakul T; Pariyawateekul P; Katanyoo K; Tanprasert P; Janweerachai W; Sangthawan D; Khunnarong J; Chottetanaprasith T; Supawattanabodee B; Lertsanguansinchai P; Srisomboon J; Isaranuwatchai W; Lorvidhaya V
J Gynecol Oncol; 2019 Jul; 30(4):e82. PubMed ID: 31074236
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; Colombo A; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Carinelli S; Provencher D; Hanzen C; Lutgens LCHW; Smit VTHBM; Singh N; Do V; D'Amico R; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
Lancet Oncol; 2018 Mar; 19(3):295-309. PubMed ID: 29449189
[TBL] [Abstract][Full Text] [Related]
10. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial.
Liang J; Bi N; Wu S; Chen M; Lv C; Zhao L; Shi A; Jiang W; Xu Y; Zhou Z; Wang W; Chen D; Hui Z; Lv J; Zhang H; Feng Q; Xiao Z; Wang X; Liu L; Zhang T; Du L; Chen W; Shyr Y; Yin W; Li J; He J; Wang L
Ann Oncol; 2017 Apr; 28(4):777-783. PubMed ID: 28137739
[TBL] [Abstract][Full Text] [Related]
11. Role of serum VEGFA, TIMP2, MMP2 and MMP9 in monitoring response to adjuvant radiochemotherapy in patients with primary cervical cancer--results of a companion protocol of the randomized NOGGO-AGO phase III clinical trial.
Braicu EI; Gasimli K; Richter R; Nassir M; Kümmel S; Blohmer JU; Yalcinkaya I; Chekerov R; Ignat I; Ionescu A; Mentze M; Fotopoulou C; Pop C; Lichtenegger W; Sehouli J; ;
Anticancer Res; 2014 Jan; 34(1):385-91. PubMed ID: 24403492
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: TORG 0503.
Kubota K; Kunitoh H; Seto T; Shimada N; Tsuboi M; Ohhira T; Okamoto H; Masuda N; Maruyama R; Shibuya M; Watanabe K
Lung Cancer; 2020 Mar; 141():32-36. PubMed ID: 31931444
[TBL] [Abstract][Full Text] [Related]
13. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant weekly carboplatin and paclitaxel followed by radical hysterectomy for locally advanced cervical cancer: long-term results.
Mori T; Hosokawa K; Sawada M; Kuroboshi H; Tatsumi H; Koshiba H; Okubo T; Kitawaki J
Int J Gynecol Cancer; 2010 May; 20(4):611-6. PubMed ID: 20686381
[TBL] [Abstract][Full Text] [Related]
15. Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.
Huang YT; Wang CC; Tsai CS; Lai CH; Chang TC; Chou HH; Lee SP; Hong JH
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):420-7. PubMed ID: 22365621
[TBL] [Abstract][Full Text] [Related]
16. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
17. Concurrent paclitaxel/cisplatin chemoradiotherapy with or without consolidation chemotherapy in high-risk early-stage cervical cancer patients following radical hysterectomy: preliminary results of a phase III randomized study.
Zhao H; Li L; Su H; Lin B; Zhang X; Xue S; Fei Z; Zhao L; Pan Q; Jin X; Xie C
Oncotarget; 2016 Oct; 7(43):70969-70978. PubMed ID: 27391158
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant carboplatin and paclitaxel after concurrent cisplatin and radiotherapy in patients with locally advanced cervical cancer.
Yavas G; Yavas C; Sen E; Oner I; Celik C; Ata O
Int J Gynecol Cancer; 2019 Jan; 29(1):42-47. PubMed ID: 30640682
[TBL] [Abstract][Full Text] [Related]
19. OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.
Provencher DM; Gallagher CJ; Parulekar WR; Ledermann JA; Armstrong DK; Brundage M; Gourley C; Romero I; Gonzalez-Martin A; Feeney M; Bessette P; Hall M; Weberpals JI; Hall G; Lau SK; Gauthier P; Fung-Kee-Fung M; Eisenhauer EA; Winch C; Tu D; MacKay HJ
Ann Oncol; 2018 Feb; 29(2):431-438. PubMed ID: 29186319
[TBL] [Abstract][Full Text] [Related]
20. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]